In the present study, we used chronic mouse model of asthma where OVA-sensitized mice were exposed to OVA twice per week over a period of 6-weeks and examined the effect of AR inhibitor, fidarestat, administered orally starting after the first OVA-challenge, on the parameters of airway remodeling. This evidence concerns the gene AR and asthma.